U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807307) titled 'Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential' on Jan. 29.
Brief Summary: Through genomic and transcriptomic sequencing techniques (whole exome sequencing, WES; whole transcriptome sequencing, WTS) patients with enrichment for KEAPness and specific gene interactions associated with it.
Study Start Date: June 04, 2024
Study Type: OBSERVATIONAL
Condition:
NSCLC
Recruitment Status: RECRUITING
Sponsor: Regina Elena Cancer Institute
Published by HT Digital Content Services with permission from Health Daily Digest....